OC 65 - Advances in the Measurement and Reversal of Anticoagulants

Moderator(s)

• 

  Will Thomas, MB BS

  Consultant haematologist
  Department of haematology
  Cambridge University Hospitals NHS Foundation Trust
• 

  Fionnuala Ni Ainle, MD, PhD

  Consultant Haematologist
  School of Medicine
  University College Dublin
  Dublin 20, Dublin, Ireland

Presentations:

• 2:45 PM – 3:00 PM

  Prediction of apixaban or rivaroxaban concentrations based on low molecular weight heparin anti-Xa activity using nomograms: a useful tool in emergency clinical situations like thrombolysis in stroke
  

  Co-Author: Charlyne BRAKTA – INSERM UMR-S-1140 / University of Paris

  Co-Author: Alain STEPANIAN – Lariboisière hospital / University of Paris

  Co-Author: Rahma ELAYEB – Lariboisière hospital / University of Paris

  Co-Author: Marie NEUWIRTH – AP-HP.Nord / University of Paris

  Co-Author: Emmanuel CURIS – Faculty of Pharmacy / University of Paris

  Co-Author: Maxime DELRUE – AP-HP.Nord / University of Paris

  Presenting Author: Virginie SIGURET, PhD, PharmD – INSERM UMR-S-1140 / University of Paris
• 3:00 PM – 3:15 PM

  Andexanet alfa is associated with a significant reduction in in-hospital mortality compared to 4F-PCC in a real-world analysis
  

  Presenting Author: Paul P. Dobesh, PharmD, FACC, FAHA, FACC, BCPS, BCCP – University of Nebraska Medical Center College of Pharmacy

  Co-Author: Craig I. Coleman, PharmD, FASHP – School of Pharmacy, University of Connecticut

  Co-Author: Julie Ulloa – Outcomes Insights

  Co-Author: Belinda Lovelace – Alexion, AstraZeneca Rare Disease

  Co-Author: Terry Dettling – Alexion, AstraZeneca Rare Disease

  Co-Author: Bruce Koch – Alexion, AstraZeneca Rare Disease

  Co-Author: Gregory J. Fermann – University of Cincinnati
• 3:15 PM – 3:30 PM

  A Phase 2 Trial Evaluating the Safety and Antithrombotic Efficacy of AB002, a First-in-class Protein C Activator in End-stage Renal Disease Patients on Heparin-free Hemodialysis
  

  Presenting Author: Norah G. Verbout, PhD – Aronora, Inc.

  Co-Author: Christina U. Lorentz – Aronora, Inc

  Co-Author: Brandon D. Markway, PhD – Aronora, Inc.

  Co-Author: Michael Wallisch – Aronora, Inc.

  Co-Author: Joseph J. Shatzel – Oregon Health & Science University

  Co-Author: Erik I. Tucker – Aronora, Inc.
• 3:30 PM – 3:45 PM

  Idarucizumab for Reversal of Dabigatran: Multicenter Real-World Experience
  

  Presenting Author: Paola A. Barzallo Burbano, MD – Hospital General Universitario Gregorio Marañón, Madrid, Spain

  Co-Author: Cristina Fernández Maqueda – Hospital Universitario Puerta de Hierro, Madrid, Spain

  Co-Author: Mar Meijón – Hospital Universitario Ramón y Cajal, Madrid, Spain

  Co-Author: Nuria Revilla – Hospital Universitario Ramón y Cajal, Madrid, Spain

  Co-Author: María Jesús Blanco Bañares – Hospital Universitario La Paz, Madrid, Spain

  Co-Author: Begoña Fernández – Hospital Universitario de Móstoles, Madrid, Spain

  Co-Author: Ramón Rodríguez González – Hospital Severo Ochoa, Madrid, Spain

  Co-Author: María Elena Sola Aparicio – Hospital Rey Juan Carlos, Madrid, Spain

  Co-Author: Belén Rosado Sierra – Hospital Rey Juan Carlos, Madrid, Spain

  Co-Author: Susana Asenjo – Hospital Clínico San Carlos, Madrid, Spain

  Co-Author: Isabel Gutiérrez Jomarrón – Hospital Universitario Príncipe de Asturias

  Co-Author: Pilar Pilar Llamas Sillero – Fundación Jiménez Diaz, Madrid, Spain

  Co-Author: Pablo Prieto Martínez – Hospital Universitario Puerta de Hierro, Madrid, Spain

  Co-Author: Raquel De Santiago Álvarez – Hospital Universitario Puerta de Hierro, Madrid, Spain

  Co-Author: José Luis Díez Martín – Deparment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

  Co-Author: Gloria Pérez Rus – Hospital General Universitario Gregorio Marañón, Madrid, Spain

  Co-Author: Cristina Pascual Izquierdo – Deparment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
• 3:45 PM – 4:00 PM

  Factors influencing anti-Xa assays in different groups of critically ill and non-critically ill patients receiving unfractionated heparin: a multicenter prospective study
  

  Co-Author: Dominique Lasne – AP-HP, Laboratoire d’hématologie générale, Hôpital Necker, F-75015 Paris, France

  Co-Author: Marie Toussaint-Hacquard – Hématologie Biologique, CHRU, Nancy

  Co-Author: Céline Delassasseigne – Laboratoire Hématologie, Hôpital Haut-Lévêque, CHU Bordeaux, France

  Co-Author: Anne Bauters – Hematologie Biologique, CHU Lille, France

  Co-Author: Claire Flaujac – laboratoire de biologie médicale- secteur hémostase - André Mignot hospital, Versailles

  Co-Author: Philippe Savard – Hématologie Biologique, CHU, Dijon Bourgogne

  Co-Author: Christine Mouton – Laboratoire Hématologie, Hôpital Haut-Lévêque, CHU Bordeaux, France

  Co-Author: Emmanuel De Maistre – Hématologie Biologique, CHU, Dijon

  Co-Author: Alain STEPANIAN – Lariboisière hospital / University of Paris

  Co-Author: Jean-Louis Georges – André Mignot hospital, Versailles

  Co-Author: Antoine Gros – André Mignot hospital, Versailles

  Co-Author: Alexandre Mansour – University Hospital of Rennes

  Co-Author: Guillaume Leroy – University Hospital of Lille

  Co-Author: Romain Jouffroy – AP-HP.Centre / University of Paris

  Co-Author: Matthieu Mattei – University Hospital of Nancy

  Co-Author: Adeline PONTIS – Department of Biological Hematology, Pontchaillou, University Hospital of Rennes, Institut de recherche en santé, environnement et travail - IRSET, Inserm UMR_S 1085,  Univ Rennes, CHU Rennes, France

  Co-Author: Marie NEUWIRTH – INSERM UMR-S-1140, Innovative therapies in Haemostasis, Université Paris Cité

  Co-Author: Emmanuel Curis – UR 7537 BioSTM (Biostatistics), Université Paris Cité, Faculté de Pharmacie, Paris, France

  Co-Author: Virginie Siguret – AP-HP.Nord / University of Paris

  Presenting Author: Isabelle Gouin-Thibault, Sr., PhD – Department of Hematology/Hemostasis, Pontchaillou University Hospital of Rennes, Univ Rennes, Irset - Inserm UMR_S 1085, Rennes, France.